-
Pfizer’s oncology pipeline looks promising.
-
The company’s newer approvals could make significant progress.
-
And its efforts to reduce expenses should help it navigate tariff-related challenges.
Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several years now. The company’s shares are down by 50% since 2022.
Some investors might see this as an opportunity to buy the stock on the dip, but that’d only be a good move if there are excellent reasons to think the stock might bounce back. There are several things investors can watch out for to determine this. Let’s consider three of the most important.
Any struggling pharmaceutical company will try to turn things around by developing newer medicines. Pfizer is no exception; its pipeline is deep, with over 100 active programs. The drugmaker is particularly focused on making a significant impact in the oncology market, one of the largest segments in the industry. That’s why Pfizer spent $43 billion to acquire Seagen, a smaller biotech that specialized in oncology.
At the time of the acquisition, Seagen had several approved cancer drugs, but it had an especially impressive pipeline for a company of its size. Pfizer’s CEO said: “We are not buying the golden eggs. We are acquiring the goose that is laying the golden eggs.” The idea was that Seagen’s innovative abilities, coupled with Pfizer’s resources and vast experience and reach in the industry, would eventually produce even better outcomes.
Pfizer has made other moves to bolster its oncology pipeline since that acquisition. Earlier this year, it signed a licensing agreement with China-based 3SBio for SSGJ-707, an investigational bispecific antibody — a niche that is increasingly gaining ground in oncology. Pfizer’s clinical and regulatory progress in this market will be crucial in the next few years. Investors should closely monitor the company’s oncology-related developments.
The drugmaker has earned approval for several new medicines in recent years. These include Abrysvo, a vaccine for the respiratory syncytial virus (RSV); cancer medicine Elrexfio; and Litfulo, which treats alopecia areata. Unfortunately, none of these is making significant contributions to Pfizer’s top line yet. That said, they haven’t been on the market for that long; all were first approved in 2023.
There’s still time for these newer products to make a more meaningful impact on Pfizer’s financial results, especially as they gain new indications. For instance, Abrysvo recently got a label expansion in Europe, allowing it to be prescribed to lower the risk of respiratory tract disease caused by RSV in people aged 18 to 59. Litfulo is undergoing clinical trials targeting Crohn’s disease, ulcerative colitis, and vitiligo. Elrexfio is also in several phase 3 studies for additional indications.
